The U.S. Food and Drug Administration has issued a new safety communication highlighting a potential seizure risk associated with certain Parkinson’s treatments, specifically medications containing carbidopa/levodopa.
According to the agency, this risk is tied to vitamin B6 deficiency, which can occur in patients taking these medications and, in rare cases, lead to seizures. As a result, the FDA is requiring manufacturers to update prescribing information with clearer warnings about this potential side effect.
The updated guidance encourages healthcare providers to check patients’ vitamin B6 levels before starting therapy and to monitor them throughout treatment. Supplementation may be recommended when deficiencies are identified.
The safety review that prompted this update identified a small number of seizure cases linked to vitamin B6 deficiency in patients using carbidopa/levodopa therapies. While the risk appears to be uncommon, the FDA’s action underscores the importance of proactive monitoring and patient-specific management when prescribing these widely used medications.
Resource: FDA issues warning of potential seizure risk from certain Parkinson’s medications